Vyvanse’s Long Shadow: Launch To Decide Fate Of Two Other Shire NDAs
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryShire is keeping two pending NDAs for new attention deficit hyperactivity disorder treatments in a sort of limbo while it waits to see if the high expectations for the launch of its d-amphetamine prodrug Vyvanse are fulfilled
You may also be interested in...
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.